T-cell therapy: A powerful tool for the management of viral infections and relapse post hematopoietic stem cell transplantation

Expert Review of Hematology

Volumn 5, Issue 5, 2012, Pages 471-473

  Kaloyannidis, Panayotis ^a,b   Leen, Ann M ^a   Papadopoulou, Anastasia ^a,b  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b G PAPANICOLAOU HOSPITAL   (Greece)

Author keywords

hematopoietic stem cell transplantation; relapse; T cell therapy; viral infections

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; CANCER RECURRENCE; CELL THERAPY; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; DRUG FATALITY; EDITORIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOCYTE TRANSFER; PRIORITY JOURNAL; T CELL THERAPY; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS INFECTION;

HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; RECURRENCE; T-LYMPHOCYTES; TISSUE THERAPY; VIRUS DISEASES;

EID: 84869201267     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.12.38     Document Type: Editorial

References (20)

1. Marmont AM, Horowitz MM, Gale RP et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 78(8), 2120-2130 (1991).
2. Abbas AK, Lichtman AH, Pober JS. Cellular and molecular immunology. In: Antigen Receptors and Accessory Molecules of T Lymphocytes. Ehlers J (Ed.), W.B. Saunders Company, PA, USA, 79-121 (2000).
3. Roddie C, Peggs KS. Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opin. Biol. Ther. 11(4), 473-487 (2011).
4. Anasetti C, Beatty PG, Storb R et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum. Immunol. 29(2), 79-91 (1990).
5. Feuchtinger T, Opherk K, Bethge WA et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 116(20), 4360-4367 (2010).
6. Tischer S, Kaireit T, Figueiredo C et al. Establishment of the reversible peptide-major histocompatibility complex (pMHC) class I Histamer technology: Tool for visualization and selection of functionally active antigen-specific CD8+T lymphocytes. Int. Immunol. 24(9), 561-572 (2012
7. Hanley PJ, Shaffer DR, Cruz CR et al. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. Cytotherapy 13(8), 976-986 (2011).
8. Warren EH, Fujii N, Akatsuka Y et al. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood 115(19), 3869-3878 (2010).
9. Bornhäuser M, Thiede C, Platzbecker U et al. Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia. Blood 117(26), 7174-7184 (2011).
10. Rezvani K, Yong AS, Tawab A et al. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood 113(10), 2245-2255 (2009).
11. Ramos CA, Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin. Biol. Ther. 11(7), 855-873 (2011).
12. Savoldo B, Ramos CA, Liu E et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptormodified T cells in lymphoma patients. J. Clin. Invest. 121(5), 1822-1826 (2011).
13. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a Phase I clinical trial. Mol. Ther. 18(4), 666-668 (2010).
14. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18(4), 843-851 (2010).
15. Di Stasi A, Tey SK, Dotti G et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365(18), 1673-1683 (2011).
16. Ciceri F, Bonini C, Stanghellini MT et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): A nonrandomised Phase I-II study. Lancet Oncol. 10(5), 489-500 (2009).
17. Micklethwaite KP, Savoldo B, Hanley PJ et al. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single cultureas protection against infection and relapse after stem cell transplantation. Blood 115(13), 2695-2703 (2010).
18. Vera JF, Brenner LJ, Gerdemann U et al. Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J. Immunother. 33(3), 305-315 (2010).
19. Gerdemann U, Katari U, Christin AS et al. Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol. Ther. 19(12), 2258-2268 (2011).
20. Gerdemann U, Keirnan JM, Katari UL et al. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol. Ther. 20(8), 1622-1632 (2012).